J&J beats Wall Street estimates on strong drug sales
Johnson & Johnson has today beaten estimates for second-quarter profit and revenue, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.
Business
• 17 Jul 24
